Apicore US LLC

Rk Pharma Solutions LLC

Veerabhadra Rao Bobbili

Ravishanker Kovi

Jayaraman Rao Kannapan

Ananda Babu Thirunavakarasu

Gaurav Yadav

Jayaraman Kannappan

Sanjay F Thakor

Shivnath Sahebrao Patil

Talluri Bhushaiah Chowdary

Anand Vijaykumar Mantri

Gaurav Kulkarni

Alaparthi Lakshmi Prasad

Vasanthakumar G Ramu

Saiyed Akeel Ahmed Shakeel Ahmed

N V Raghavalu Dusanapudi

Piyush Fadadu

Sai Saisuryanarayana Donthukurthi

Srikrishna Apar

Shivam Saroj

Sandeep Aher

Methods for preparing degarelix acetate are provided that include the steps of providing a suitable resin; deprotecting the resin with a diethylenetriamine solution; reacting sequentially the deprotected resin with different Fmoc protected amino acids; deprotecting the amino acid in each sequence with a diethylenetriamine solution in a stepwise fashion to yield a degarelix crude compound; and purifying the degarelix crude compound to yield pharmaceutically acceptable degarelix acetate. Methods of preparing degarelix acetate-mannitol premix and the resulting degarelix acetate-mannitol premix are also provided.

Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix

Processes are disclosed for making vortioxetine and pharmaceutically acceptable salts thereof. A propylene glycol solvate of vortioxetine hydrobromide is disclosed. A novel crystalline form of vortioxetine hydrobromide propylene glycol solvate, designated form AC1, is disclosed along with a method for making same. Form AC1 may be characterized by an x-ray powder diffraction pattern with peaks at about 19.64, 22.85, 25.51, 29.57, 30.18&#xb1;0.2 degrees 2-theta.

Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts

Novel crystalline ponatinib hydrochloride forms designated Form alpha and Form beta are disclosed. Form alpha is characterized by data selected from an XRPD pattern with peaks at about 6.5, 9.0, 12.25, 14.4, 16.70, 19.6, 22.2, 24.5, 28.2&#xb1;0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG.; and/or a combination thereof. Form beta is characterized by data selected from an XRPD pattern with peaks at about 10.7, 15.2, 15.8, 16.4 23.1, 25.0, 27.8&#xb1;0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG.; and/or combinations thereof. Processes for making Form alpha and Form beta are disclosed.

Polymorphs of ponatinib hydrochloride

Racemization-free methods are disclosed for the synthesis of carfilzomib. Novel intermediates and methods of making carfilzomib employing fragment condensation using the novel intermediates are disclosed. Amorphous carfilzomib and methods of making same are disclosed.

Methods of making carfilzomib and intermediates thereof

Growing community of inventors

Andhra Pradesh, India

Veerabhadra Rao Bobbili